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Graves’ disease is an autoimmune thyroid disease and a common cause of 
hyperthyroidism. Thyroid hormones have multiple adverse effect on cardiovascular 
system through many direct and indirect mechanisms. They increases heart rate, 
cardiac contractility, systolic and mean pulmonary artery pressure, cardiac out-
put, diastolic relaxation, and myocardial oxygen consumption, whereas decrease 
systemic vascular resistance and diastolic pressure. All these hemodynamic changes 
in cardiovascular system can eventually lead to heart failure, tachyarrhythmias, 
systemic and pulmonary hypertension, if left untreated. Cardiovascular complica-
tions of Graves’ disease are frequent and important cause of increased morbidity 
and mortality. This chapter reviews the cardiovascular complications of Graves’ 
hyperthyroidism with underlying mechanisms and treatment.
Keywords: Graves’ disease, cardiac complications, heart failure, thyrotoxicosis, 
pulmonary hypertension
1. Introduction
Robert Graves identified the association of goiter, palpitations, and exophthalmos 
in 1835 [1]. Although the cause of Graves’ hyperthyroidism was initially thought to be 
thyrotropin, it was later understood that Graves’ hyperthyroidism was clearly caused 
by thyroid stimulating antibodies-IgG- which bind to and activate to thyrotropin 
receptors on thyroid cells [2]. Although the incidence is not known exactly, manifest 
hyperthyroidism is common and affects 2–5% of the population [3]. Approximately 
60–80% of hyperthyroidism cases have Graves’ disease due to regional factors, par-
ticularly iodine intake. Over a period of 20 years, the incidence in women is around 
0.5 per 1000 annually and the most frequent onset age gap is 40–60; hence, Graves’ 
disease is most common autoimmune disorder in the United States [4]. Graves’ dis-
ease rate in men is between 1/5 and 1/10 and equal to women; however, the disease 
is unusual in children. The prevalence is lower in African-Americans in reference to 
Asians and Whites [5]. Graves’ disease has similarities with autoimmune hypothyroid-
ism, including high serum concentrations of antibodies against thyroglobulin, thyroid 
peroxidase, and possibly the sodium-iodide cotransporter in thyroid tissue. These 
antibodies’ concentrations vary among patients, and the antibodies themselves may 
modify the stimulatory effects of thyroid-stimulating antibodies. In some patients, 
the simultaneous production of antibodies that block the thyrotropin receptor reduces 
the stimulatory action of thyroid-stimulating antibodies. For these reasons there is no 
direct correlation between serum concentrations of thyroid-stimulating antibodies and 
serum thyroid hormone concentrations in patients with Graves’ hyperthyroidism [6].
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Thyroid hormones have major effects on the heart and cardiovascular system 
through many mechanisms. They increase heart rate, cardiac contractility, systolic 
and mean pulmonary artery pressure, cardiac output, diastolic relaxation, and 
myocardial oxygen consumption, and reduce systemic vascular resistance and 
diastolic pressure [7]. Cardiovascular symptoms have been showing some signs of 
patients clinical presentation for the physicians: palpitations, exercise intolerance, 
dyspnoea, angina-like chest pain, peripheral edema and congestive heart failure are 
common symptoms of hyperthyroidism [8, 9]. In hyperthyroid patients mortality is 
increased by 20% and the major causes of death are cardiac problems [10].
2. Graves’ hyperthyroidism
The clinical manifestation and the laboratory findings aid to establish the 
diagnosis of Graves’ disease in hyperthyroidism patients. Especially, serum thy-
rotropin levels is very beneficial marker in hyperthyroidism because secretion 
is thyrotropin is substantially reduced by small amount of elevation in thyroid 
secretion. Nevertheless, the diagnosis should be confirmed via the serum free 
thyroxine measurements [11]. However, in the early periods, only triiodothyronine 
increase may occur; considering this condition serum free triiodothyronine levels 
should be examined in the presence of normal serum free thyroxine and low serum 
thyrotropin concentrations. On the other hand, serum total thyroxine and triiodo-
thyronine measurements are not as reliable as aforementioned markers because the 
certain drug use may cause elevated values in thyroid hormone–binding proteins. 
Establishing the diagnosis in a patient with hyperthyroidism is shown here:
3. Algorhythm for the diagnosis of suspected Hyperthyroidism
In the first step: Measure serum thyrotropin and free thyroxine
1. Low serum thyrotropin and normal free thyroxine- → Measure serum free 
triiodothyronine:
A. Normal serum free triiodothyronine; Subclınıcal Hyperthyroidism
B. High serum free triiodothyronine- → Triiodothyronine Hyperthyroidism
2. Low serum thyrotropin and high free thyroxine- → Hyperthyroidism
Diagnosis of Graves’ hyperthyroidism was established for patients with bio-
chemical evidence of overt hyperthyroidism, i.e. high levels of serum free T4, free 
T3, TSH < 0.1 mIU/l accompanied by at least two of following parameters: diffuse 
goiter, Graves’ ophthalmopathy, increased level of anti-TSH receptor antibodies 
(TRAb), antithyroid peroxidase antibodies (TPOAb).
4. Pathogenesis
4.1 Cardiac effects, molecular and cellular mechanisms
Cellular and molecular mechanisms by which thyroid exerts its action on 
almost every cell and organ in the body have been well studied [12]. Thyroid gland 
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maintains T4 and T3 excretion according to TSH levels. The thyroid gland primarily 
secretes T4 (≈85%), which is converted to T3 by 5′-monodeiodination in the liver, 
kidney, and skeletal muscle. The heart function is mainly based on T3, because of 
the absence of myocyte intracellular deiodinase activity and T3 migrates into the 
myocyte instead T4 [13]. Then, the activity of T3 is administered after binding to 
thyroid hormone nuclear receptors (THRs). Then, these receptor proteins binds to 
thyroid hormone response elements (TREs) in the promoter regions of positively 
regulated genes thus regulates the transcription [12, 14]. T3 acts on THRs in the 
nucleus, and creating dimers of 9-cis-retinoic acid receptor (RXR) [15]: the formed 
complexes recognize some specific DNA consensus sequences, TREs, located in 
the enhanced region of the genes to initiate the transcription [16]. Although, TRs 
considered as a steroid hormone receptors, unlikely, bind to TREs regardless of 
whether ligand is present or not. TRs connect to TREs with 1 of 3 isoforms of retinoid 
X receptor (RXRα, RXRβ, or RXRˠ) as homodimers or heterodimers [17]. While 
bound to T3, TRs induce transcription, and in the absence of T3 they repress tran-
scription. Thyroid hormone upregulates α, but downregulates β-chain in myocytes 
[18]. Negatively regulated cardiac genes such as β-myosin heavy chain and phosphol-
amban are induced in the absence of T3 and repressed in the presence of T3 [19, 20].
Thyroid hormone has a direct impact on cardiac activity through myocytes by 
achieving structural and regulatory gene expressions. The 2 isoforms of a contrac-
tile protein pertain to thick filament of cardiac myocyte is codified by myosin heavy 
chain gene.
The sarcoplasmic reticulum Ca2+-ATPase and its inhibitor, phospholamban, 
regulate intracellular calcium cycling. Together they are largely responsible for 
enhanced contractile function and diastolic relaxation in the heart [21]. T3 lev-
els are also intimately associated with the β –adrenergic receptors and sodium 
 potassium ATPase.
Thyroid hormone cause extranuclear genome-free effects on both the cardiac 
myocyte and systemic vasculature. These effects of T3 can occur rapidly and do 
not involve
TRE-mediated transcriptional events [22]. These T3-mediated effects include 
changes in various membrane ion channels for sodium, potassium, and calcium, 
effects on actin polymerization, adenine nucleotide translocator-1 in the mitochon-
drial membrane, and a variety of intracellular signaling pathways in the heart and 
vascular smooth muscle cells (VSM)A27. The collaboration of the both genomic and 
nongenomic features of the T3 activity regulate the cardiovascular system.
Thyroid hormone express its activity in myocytes via various TREs, such as 
alpha myosin heavy chain fusion (MHC-α), sarcoplasmic reticulum calcium-
activated ATPase (SERCA): which maintains calcium uptake during diastole, by 
calcium activated ATPase and phospholamban -the inhibitory cofactor- [23, 24] 
the cellular membrane Na-K pump (Na-K ATPase), β1 adrenergic receptor, car-
diac troponin I, and atrial natriuretic peptide (ANP), and some genes are also 
suppressed, such as β-myosin heavy chain fusion (MHC-β), adenylyl cyclase (IV 
and V) and the Na-Ca antiporter [25–27]. The final effect of thyroid hormones 
in animal studies-and also similar effects have also been observed in preliminary 
human studies-is increased rate of V1 isoform of MHC (MHCα/α) synthesis that 
is characteristically faster in myocardial fiber shortening [28–30]. Thyroid hor-
mones enhance myocardial relaxation by upregulating expression of SERCA, and 
downregulating expression of phospholamban. Cytoplasmic calcium concentration 
substantially decrease at the end of the diastole. This cause a higher magnitude 
of systolic transient of calcium; therefore heightens capacity for actin-myosin 
subunits activation. As a supportive evidence, a phospholamban deficient mice 
demonstrated no tachycardia in response to thyroid hormone treatment [31] on the 
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plasma membranes, T3 has extragenic actions on various ion channels such as Na/K 
ATPase, Na/Ca++ exchanger, and voltage gated K channels (Kv 1.5, Kv 4.2, Kv 4.3) 
affecting  cardiovascular  hemodynamics [32].
For instance, Na channel activation period augments in myocardium; this cause 
prolonged intracellular Na uptake and increased secondary Na-Ca antiporter func-
tions. Thus underlying mechanism under the inotropic effect may be comparatively 
revealed [33]. T3 effects on L-type calcium channels directly by abbreviating the 
action potential period [34, 35]. The augmentation of β-adrenergic receptors the 
may be the main reason for the intense inotropic response to the thyroid hormones 
[36]. Although, G protein and β-receptors increased; circulating cathecolamine 
measurements remained similar [37]. The sensitivity of the cardiovascular system 
to adrenergic stimulation is not changed by thyroid hormones. The changes in the 
heart rate result from both an increase in sympathetic tone and decrease in parasym-
pathetic tone [38, 39]. Rapid response for the Cardiac and vascular structures of the 
thyroid hormone response was not sufficiently clarified by genomic effects [40–42].
Hyperthyroidism elicits rapid hemodynamic response as well as non-genomic 
changes in plasma membranes. Authors, indicate that thyroid hormone stimulates 
acute phosphorylation of phospholamban. This pathway may be slightly respon-
sible the collaboration between thyroid hormone and the adrenergic effects on the 
heart [43].
The use of β-adrenergic receptor antagonists in hyperthyroidism reduced heart 
rate, but systolic or diastolic contractile performance remained similar, support-
ing the direct cardiac muscle effect of thyroid hormone [44]. Meanwhile, thyroid 
hormone impacted on the sinoatrial node and caused oxidative stress in experimen-
tal studies. The heart rate is parallel to the sinoatrial activity, lower threshold for 
atrial activity, and shortened atrial repolarization [45]. Hemodynamic changes such 
as volume preload increase following the renin-angiotensin system activation or 
augmented contractility due to improved metabolic demand or the reduction in the 
direct effect of the thyroid hormone on heart muscle, decreased systemic vascular 
resistance caused by triiodothyronine-induced peripheral vasodilatation, lead to a 
dramatic impairment in cardiac output [7, 46, 47].
Preload is increased in a state of hyperthyroidism, and the reduced peripheral vas-
cular resistance and elevated heart rate lead to increased cardiac output. The reduction 
in systemic vascular resistance lead to impaired renal perfusion pressure thus activates 
renin-angiotensin-aldosterone system (RAAS), hence sodium reabsorption and 
blood volume increase. In turn, this leads to increased preload, decreased afterload, 
and ultimately a significant increase in stroke volume [48]. Furthermore, it is sug-
gested that T3 enhances renin substrate synthesis in liver and stimulates the cardiac 
expression of renin mRNA, leading to elevated cardiac renin levels and angiotensin 
II independent from the circulating renin and angiotensin. The expression of angio-
tensin II receptors in the myocardium increases in the hyperthyroid state [49]. These 
hemodynamic responses trigger atrial stretch trigger and stimulate atrial natriuretic 
peptide (ANP) secretion, resulting in more vasodilation. Such changes figure out a 
critical role of the myocardial RAAS in thyroxine-induced cardiac hypertrophy as well 
as potential therapeutic implications of agents that block this system.
Adrenomedullin, a polypeptide of 52 amino acids, is a potent vasodilator 
and thyroid gland is responsible for regulation transcription of adrenomedullin. 
Serum levels therefore proportionally increase in thyrotoxicosis [50]. Interestingly, 
however, Diekman and colleagues demonstrated that although systemic vascular 
resistance (SVR) is decreased and adrenomedullin is increased in thyrotoxicosis, 
restoration of euthyroidism normalized SVR but was not correlated with plasma 
adrenomedullin levels [51]. In the present study, only T3 was an independent 
determinant of SVR.
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5.  Clinical manifestations and Hemodynamic Effects of Thyroid 
Hormones
The clinical manifestations and the severity of the disease are strongly correlated 
to the duration of Graves’ disease and the patient age. More than half of the patients 
are symptomatic in time of diagnosis. The most frequent findings may be counted as 
nervousness, fatigue, a rapid heartbeat or palpitations, heat intolerance, and weight 
loss respectively. By age, weight loss and decreased appetite are frequently observed, 
whereas irritability and heat intolerance are less frequent. Atrial fibrillation is 
occasional below age 50. A firm, diffuse goiter of variable size presents in the 90% 
and 75% patients, respectively; when 50 years of age was hold as threshold [52].
Thyroid hormone has cardiovascular effects that include decreased SVR and 
increased resting heart rate, left ventricular contractility, and blood volume. 
Thyroid hormone reduce the peripheral arteriolar resistance and decrease mean 
arterial pressure, through the renin-angiotensin-aldosterone system. Also, T3 
increases erythropoietin synthesis, which leads to an increase in red cell mass. 
Harmony of these effects contribute to increase in blood volume and preload. In 
hyperthyroidism, these combined mechanisms maximize cardiac output up to 
300% higher when compared to control group. In hypothyroidism, the cardio-
vascular effects are diametrically opposite and cardiac output may decrease by 
30–50% [53].
Thyroid hormone shows its affects rapidly and non-genomic pathway through 
heart and blood vessels. Beyond what is reported above, In the peripheral vascular 
system, the elevated oxygen consumption, metabolic remnants and relaxation of 
arterial smooth muscle fibers by thyroid hormone eventuate in peripheral vasodi-
latation [32]. This dramatical decrease in peripheral vascular resistance (PVR) has 
a great role in hemodynamic changes caused by thyroid hormones [54]. Decreased 
PVR results in bradycardia, a selective increased blood flow towards visceral 
organs eventually, cause a decrease in diastolic pressure thus widen pulse pressure. 
Vasodilatation without elevated renal blood flow results in a reduction in renal 
perfusion thus activates the renin-angiotensin cascade. Hence, sodium retention 
and increased blood volume occurs [46]. Moreover, thyroid hormones effects on 
erythropoietin secretion; hence cause to increase in red cell mass and the blood vol-
ume [55]. Increased diastolic relaxation and blood volume improves left ventricular 
end-diastolic volume (LVEDV). Reduced PVR and increased LVEDV in together, 
augment preload and impair afterload; thus the stroke volume increases. Improved 
stroke volume and heart rate increase cardiac output, which cannot be only a 
consequence of an increased metabolic rate [56]. The correlation between systemic 
vascular resistance and systemic blood flow in hyperthyroidism is investigated 
previously, focusing on arterial vasoconstrictors in particular. On the contrary to 
the normal subjects, atropine and phenylephrine succeeded to decrease peripheral 
blood flow and cardiac output by 34% in hyperthyroidism group [57].
Studies including large cohorts determined that blood pressure levels widened 
throughout the entire spectrum of thyroid function [58]. In this study, Asvold et al. 
reported a linear correlation between TSH and both systolic and diastolic blood 
pressure, however other studies did not find a correlation [59]. Basal metabolism 
is triggered by thyroid hormones and a complete response develops in almost 
every tissue and organ system in the body, as a consequence of increased metabolic 
demands, hemodynamic changes in cardiac output, SVR, and blood pressure occur. 
On several counts, such changes are similar to the physiological response to exercise 
[60]. Pulse pressure tends to be widened in case of hyperthyroidism. Some current 
reports have determined that despite the low SVR in hyperthyroidism, arterial 
stiffness is increased [61]. Thus excess thyroid hormone typically enforce systolic 
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blood pressure to rise, the increase can therefore be quite dramatic in older patients 
with atherosclerosis led to impaired arterial compliance. Hyperthyroidism has been 
identified as the second most common reason for isolated systolic hypertension 
[62]. Efficient hyperthyroidism treatment and the administration of β-blockade 
to achieve normocardia reverses these changes. In hypothyroidism, endothelial 
dysfunction and impaired VSM relaxation eventuate in lower SVR [63]. These 
effects lead to diastolic hypertension in ≈30% of patients, and thyroid hormone 
replacement therapy restores endothelial-derived vasorelaxation and blood pres-
sure to normal in most [64].
Sinus tachycardia is the most frequent ECG disorder. Intraventricular conduc-
tion delay in the form a right bundle branch block is observed in approximate of 
15% patients.
Alternative, unknown reasons may also be present for the occurrence of atrio-
ventricular block Increased dispersion of QT interval corrected by the heart rate 
(QTcD) and pulmonary hypertension may also be present, however underlying 
mechanisms are yet unclear; the similar cardiac and hemodynamic changes accom-
panying with the autoimmune disorders in Graves’ patients probably contribute to 
conduction problems [65]. Hyperthyroidism leads to shortened action potential and 
altered expression of L-type calcium channel 1D, enhances Na and K permeability, 
and affects Na pump density [66]. The forced preload increase and altered total 
blood volume impose burden on cardiac workload, hence frequently myocardial 
hypertrophy develops.
6. Graves’ disease and atrial fibrillation
Patients with hyperthyroidism manifest more premature supraventricular 
depolarization and premature atrial complex (PAC; also referred to a premature 
atrial beat, premature supraventricular complex, or premature supraventricular 
beat), more nonsustained supraventricular tachycardias, and reduced heart rate 
variability [67]. The reduced variability is probably occurs as a consequence of 
decreased parasympathetic tone. These electrical stimulates may lead to paroxysmal 
atrial tachycardia, atrial fibrillation, and atrial flutter. The most frequent rhythm 
disorder is sinus tachycardia in hyperthyroidism [43]. Its clinical impact is over-
shadowed by atrial fibrillation. The rate of atrial fibrillation (AF) and other rare 
forms of supraventricular tachycardia in this disease varies between 2% and 20% 
The prevalence of atrial fibrillation in hyperthyroidism was determined as 13.8%, 
however peaked at up to 15% in patients over the age of 70 years. These results is 
significantly higher when compared to the rate of 2.3% in control group [66–69]. 
Atrial fibrillation often coexists with a rapid ventricular response. The occurrence 
of AF is more frequent in men and significantly increases with age, over 40 years in 
particular [69]. A current study revealed that the AF rate was below 2% in a cohort 
includes more than 13 k cases with hyperthyroidism. Early stage of disease or rec-
ognition may contribute to these result [70]. A stepwise increase in the prevalence 
was observed in the analysis based on age, especially peaked at ≈15% in patients 
>70 years old. This findings support data from the cohort of 40.628 hyperthyroid 
patients in the Danish National Registry. This database revealed that although 8.3% 
of the patients demonstrated an atrial fibrillation; male gender, the presence of 
ischemic or valvular heart disease or congestive heart failure were associated with 
the highest risk rates. Apparently, subclinical (mild) hyperthyroidism involves 
similar relative risk for atrial fibrillation as does overt disease [68]. This dilemma 
may be interpreted in favor of other accompanying diseases that occur in the older 
population. In unselected patients with atrial fibrillation, less than 1% were the 
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consequence of over-hyperthyroidism [71]. Consequently, although the abnormal 
thyroid function levels seems less reliable and indicative in the new-onset atrial 
fibrillation, establishing an euthyroid state and achieving sinus rhythm, justifies the 
value of TSH examining [7].
The left atrial size is enlarged in most of the patients with hyperthyroidism and 
AF rather than hyperthyroid people with sinus rhythm. Hyperthyroidism should 
not be accepted as the only reason for developing the new onset AF and possible 
underlying organic heart diseases should be investigated to avoid as serious car-
diovascular events such as angina or heart failure. In an experimental study, con-
nexin-40, a gap junction protein of myocardium which is essential for the transport 
of electrical activity upregulated by thyroid hormone in rats. This pathway may 
contribute to atrial fibrillation development in hyperthyroidism [72].
Atrial fibrillation generally reverts to sinus rhythm when an euthyroid state 
established. On the other hand, in young and early diagnosed patients β-Adrenergic 
blockade may be sufficient to regulate the ventricular rate. Higher dose may be 
required in case of elevated plasma clearance of β-blockers. Propranolol has 
an additional advantage by blocking T4 - T3 conversion in peripheral tissues. 
Nevertheless, cardio-selective β-blockers have a longer half-life and have similar 
cardiac effects. Intravascular administration of calcium blockers should be avoided 
considering the possible risk of a further fall in PVR: channel blockers, may cause 
potential adverse cardiovascular events such as blood pressure reduction via 
developing relaxation through smooth muscle cells of the resistance arterioles. 
Such treatment has been linked to acute hypotension and cardiovascular collapse 
[73]. Treatment of atrial fibrillation in the setting of hyperthyroidism includes β 
-adrenergic blockade. This can be accomplished with β 1-selective or nonselective 
agents, even in peroral usage, whereas treatments such as antithyroid therapy or 
radioiodine, which lead to a restoration of a chemical euthyroid state [7]. Although 
digitalis was an option in the treatment of hyperthyroidism and coexisting atrial 
fibrillation, due to the increased digitalis clearance and decreased sensitivity of 
the hyperthyroid heart to digitalis necessitated higher doses for optimal treat-
ment beside leading to less predictable responses [74, 75]. How much risk does the 
systemic embolization include in the setting of thyrotoxicosis is yet unclear. It is 
still controversial whether to administer an anticoagulant therapy in patients with 
AF is efficient to prevent systemic embolization. Accordingly, each patient should 
be evaluated individually considering the risk of bleeding over embolization [76]. 
Hyperthyroidism in younger patients without any cardiac disease except for AF, 
the risk of anticoagulant therapy may exceed its benefits. However, it would be 
wise to administer anticoagulant drugs to older patients with previously diagnosed 
or suspected heart diseases or AF with longer duration. Oral anticoagulants doses 
should be trimmed considering that hyperthyroid patients will require less medi-
cation than euthyroid ones, due to faster elimination of vitamin-K dependent 
clotting factors [77]. Early diagnosis and full treatment radioiodine or thioureas 
demonstrated a reversion to sinus rhythm most patients within 2 to 3 months [70]. 
Older patients (>60 years old) with atrial fibrillation with longer duration are more 
resistant to spontaneous reversion to sinus rhythm. For this reason, electrical or 
pharmacological cardioversion are advised to attempt if the AF continues after an 
euthyroid state achieved chemically. Following an adequate treatment most of the 
patients turn into sinus rhythm permanently. Disopyramide (300 mg/d) adminis-
tration after successful cardioversion, contribute to remain in sinus rhythm when 
compared to those not treated [76].
Reversion and maintenance from AF to sinus rhythm is unusual before the 
euthyroid state is achieved; therefore electrical cardioversion should be avoided 
before euthyroid condition. In another experimental study, the authors remarked 
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the downregulator effects T3 via connexin-43 phosphorylation in diabetic rats. 
Thus, cardiac adaption to hyperglycemia reduced and the heart become prones to 
ventricular arrhythmias [78].
7. Graves’ disease and heart failure
Early manifestations regarding heart failure may be present in patients with 
hyperthyroidism [7, 14, 79]. Majority of the patients with hyperthyroidism suffer 
from exercise intolerance and exertional dyspnea, due to the loss of skeletal and 
respiratory muscle strength. Hyperthyroid patients can demonstrate congestive 
heart failure symptoms regardless of prior cardiac injury. This phenomenon has 
inaccurately identified “high-output heart failure,” in the presence of paradoxical 
features involving enhanced cardiac contractility and output characterized by thyroid 
hormone excess [7]. Decreased cardiac contractility, reduced diastolic compliance, 
and pulmonary congestion are true manifestations of the heart failure however these 
can be consequences of severe and chronic hyperthyroidism, tachycardia, and atrial 
fibrillation also [80–82]. The use of “high output heart failure” has not abandoned in 
late decades, considering the potential of the heart to enhance the output at both rest 
and exercise. However, In the setting of low vascular resistance and decreased preload, 
cardiac functional reserve is compromised thus lose the capacity of accommodating 
the demands of maximal or even submaximal exercise [83]. High-output heart failure 
may demonstrate dyspnea on exertion, fatigue, and fluid retention with peripheral 
edema, pleural effusion, hepatic congestion, and PAH [82]. Heart failure develops 
approximately in the 6% of thyrotoxic patients. Beyond that, dilated cardiomyopa-
thy with reduced left ventricular systolic dysfunction occurs less than 1%, due to a 
tachycardia-mediated mechanism causing an elevated cytosolic calcium levels during 
diastole with impaired contractility of the ventricle and diastolic dysfunction, often 
with tricuspid regurgitation [84]. A research conducted by Yue et al., diastolic dys-
function was found to be more prominent in thyrotoxic patients older than 40 years 
of age, whereas in younger ones a demonstrated a reduction in peripheral vascular 
resistance and improved cardiac output were outstanding [85]. However, severe and 
chronic hyperthyroidism may exaggerate sinus tachycardia or atrial fibrillation; hence, 
produce rate-related left ventricular dysfunction and heart failure [86]. This clarifies 
the reason why several patients manifesting the combination of hyperthyroidism, low 
cardiac output, and impaired left ventricular function had AF at the time of diagnosis 
[7]. However, pre-existent ischemic or hypertensive heart disease may also contribute 
the to the development of heart failure in hyperthyroid patients [14, 86].
Mitral valve prolapse is more frequently reported in patients with Graves’ dis-
eases. The latter may be a predisposing factor for the elonged the left atrial diameter 
and atrial fibrillation [87]. The risk for AF which may lead to congestive heart 
increases in the presence of low TSH levels, especially among patients over 60 years 
old [88, 89]. The high prevalence of pulmonary artery hypertension that comprises 
several signs of heart failure, such as neck vein distension and peripheral edema, 
may be caused by right heart strain [90, 91]. Similarly, reduced pulmonary com-
pliance and skeletal muscle dysfunction may lead to the exercise intolerance and 
exertional dyspnea in such patients [14]. Distinctively, thyrotoxic cardiomyopathy 
represents a myocardial damage that caused by toxic effects as a result of exces-
sive thyroid hormone activation. This condition leads to dynamic and structural 
changes such as myocyte energy production, intracellular metabolism, and myofi-
bril contractile function. Left ventricular hypertrophy, heart rhythm disturbances, 
primary atrial fibrillation, dilation of the heart chambers, heart failure, PAH, and 
diastolic dysfunction constitutes the main manifestations [48].
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Although, β-adrenergic blockage was contraindicated in previous decades in the 
treatment of thyrotoxic cardiac events, nowadays the use of such drugs considered 
as first-line therapy [92]. Digitalis and diuretics are not recommended in the heart 
failure accompanying pulmonary congestion [60].
The definitive treatment option for the hyperthyroidism is 131I-radioiodine [93]. 
Optimal hyperthyroidism treatment goals to establish an euthyroid state commonly 
represents a recovery from atrial fibrillation to sinus rhythm and a dissolution of the 
cardiac manifestations [76, 79]. Studies pointing out how crucial is an adequate and 
sufficient treatment concluded that the cardiovascular complications arising from 
thyrotoxicosis are the primary cause of death [94].
8. Graves’ disease and arterial hypertension
Thyroid hormone causes decreased resistance in peripheral arterioles through 
a direct effect on VSM cells and decreased mean arterial pressure, which, when 
sensed in the kidneys, activates the renin-angiotensin-aldosterone system and 
increases renal sodium absorption. T3 also induces erythropoietin synthesis, which 
leads to an increase in red cell mass. These changes combine to promote an increase 
in blood volume and preload. Hyperthyroidism has been identified as the second 
most common reason for isolated systolic hypertension [62]. Because of the revers-
ible effects of hyperthyroidism hypertension, efficient hyperthyroidism treatment 
and the administration of β-blockade to achieve normocardia reverses hyperten-
sion, heart rate variability and arrhythmias. Iryna Tsymbaliuk et al. [95] reported 
that there are 95% arterial hypertension between Graves’ hyperthyroidism patients, 
especially demonstrating high systolic blood pressure, as result of low vascular 
resistance, elevated resting heart rate and blood volume due to excess of thyroid 
hormones [95, 96]. Moreover, they showed that arterial hypertension was devel-
oped secondary to Graves’ hyperthyroidism and associated with diminished quality 
of life. Restoring of euthyroid state resulted in elimination of arterial hypertension 
or stabilization of blood pressure levels in patients with a history of arterial hyper-
tension, which is consistent with other studies.
The role of euthyroidism restoration is supported by findings from other studies 
showing the direct effect of hyperthyroid state on the cardiovascular system; in 
animal studies, the excess of thyroid hormones had a major impact on the cardio-
myocytes, whereas beta-adrenergic or angiotensin receptor stimulations played a 
minor role [79, 97]. And in the study, as a result, improvement of cardiovascular 
parameters in relatively short follow up time was achieved after restoring of euthy-
roid state by antithyroid therapy accompanied by administration of beta-blockers 
and ACE inhibitors.
9. Graves’ disease and pulmonary hypertension
About 1/5 of pulmonary hypertension cases are shown to be concomitantly occur-
ring with thyroid disease [98]. Pulmonary artery hypertension (PAH) is identified as 
mean pulmonary arterial pressure levels higher than 25 mm Hg at rest [81]. Increased 
pressure in the left atrium is transmitted backwardly to pulmonary veins. This acti-
vates baroreceptors ending up with a reflex contraction in the arterioles. Elevated 
pulmonary artery pressure aggravates the right ventricular workload. This overload 
forces the right ventricle to contract laboriously to maintain blood flow towards pul-
monary vasculature. However, this process eventually leads to increased pulmonary 
resistance and PAH [48]. Although, current knowledge regarding hemodynamics of 
Graves’ Disease
10
PAH in hyperthyroidism has not well explained yet, decrease in PAH after establishing 
an euthyroid state may be considered as a supportive evidence for a causal relation-
ship [99]. A current study asserts a direct relation between TSH receptor antibodies 
and PAH, thus a possible autoimmune-mediated pulmonary vascular remodeling 
may be conducted [101]. Hyperthyroidism should be excluded in patients with PAH; 
moreover, in case of coexisting hyperthyroidism and dyspnea, every patient should be 
examined for PAH either [98, 100].
PAH has been associated with thyroid dysfunction, mainly hyperthyroidism. It 
has been suggested that SVR lowering effect of thyroid hormone may not occur in 
the pulmonary vasculature [60]. PAH and atrioventricular valve regurgitation have 
been both documented with a high prevalence [90]. Various articles have revealed 
that hyperthyroidism may manifest as right heart failure and tricuspid regurgita-
tion [91]. A research including of 23 cases with hyperthyroidism originating 
from Graves’ disease documented that 65% of those patients had PAH. Following 
an adequate treatment for the Graves’ disease, pulmonary artery pressure levels 
returned to normal values in almost all patients [100, 101].
Right heart failure and peripheral edema accompanying hyperthyroidism may 
be reasoned by this reversible increase in pulmonary artery pressure [60, 91]. 
Primary pulmonary hypertension is defined as the levels of pulmonary artery 
pressure above 25 mm Hg at rest and 30 mm Hg during exercise and frequently seen 
in young women. It has a progressive nature and mostly leads to right heart failure. 
A link between pulmonary hypertension and thyroid disease (i.e., hypothyroidism 
and hyperthyroidism) has been elucidated in recent [102]. Hypothyroidism rate 
was determined as 22% in a study including 40 patients with primary pulmonary 
hypertension [103]. There are several evidences indicating the importance of the 
autoimmune disease’s role in both hypothyroid and hyperthyroid linked cases of 
primary pulmonary hypertension [91, 101, 103]. Thyroid dysfunction therefore 
should always be examined in the presence of primary pulmonary hypertension.
10. Thyroid hormone effects on lipid metabolism
Increased serum lipid levels in hypothyroidism is well-known. Hypothyroidism 
causes hypercholesterolemia especially augments low-density lipoproteins (LDL) 
and apolipoprotein B. Although, estimated prevalence of overt hypothyroidism in 
patients with hypercholesterolemia is between 1.3% to 2.8%, hypercholesterolemia 
is observed in 90% of the patients with hypothyroidism [104]. Altered lipid profile 
levels manifest even in subclinical hypothyroidism. Some authors revealed revers-
ible increased LDL levels in subclinical hypothyroidism after thyroid hormone 
replacement. On the contrary, some other studies have determined no changes in 
LDL levels despite increased total cholesterol levels in subclinical hypothyroidism 
[105]. The underlying mechanisms of the hypercholesterolemia in hypothyroidism 
involves impaired fractional clearance of LDL by decreased LDL receptors and 
receptor activity in the liver [106]. Cholesterol catabolism is regulated by choles-
terol 7α-hydroxylase [107]. This liver-origin enzyme has a negative correlation with 
T3 and may reduce catabolism and cause elevated serum cholesterol levels associ-
ated with hypothyroidism [103]. The increased serum lipid levels in subclinical 
hypothyroidism are strongly associated with increased cardiovascular risk [108]. 
This high risk may be reversed by thyroid hormone replacement therapy to establish 
euthyroid condition [106]. If left untreated, the dyslipidemia accompanying with 
the diastolic hypertension associated with hypothyroidism lead the patient prone to 
atherosclerosis [53, 86].
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11. Subclinical hyperthyroidism and heart
The impact of thyroid hormones especially the subclinical hyperthyroidism on 
cardiovascular system faces an ever-increasing interest in last decades. Subclinical 
hyperthyroidism represents low serum TSH levels accompanying with normal 
serum free T4 and T3 concentration and its prevalence varies from 0.6–16% [109]. 
Persistent abnormal TSH measurements have to be re-examined within 2–3 months 
from initial values [109, 110]. There are two main categories regarding subclinical 
hyperthyroidism: Grade 1 defines a mildly low serum TSH (0.1–0.45 mIU/L) levels 
whereas Grade 2 represent lower levels of serum TSH (< 0.1 mIU/L). Subclinical 
hyperthyroidism may have exogenous or endogenous etiology. Exogenous origin 
mainly occurs as a result of a TSH suppressive therapy (or excessive use of levothy-
roxine) for thyroid carcinoma. Endogenous reasons resembles overt hyperthyroid 
state causes including mild Graves’ disease, multinodular goiter, and autonomous 
functioning thyroid nodule. Various authors have evaluated the effects of subclini-
cal hyperthyroidism on cardiovascular and skeletal systems, particularly in older 
populations. Nanchen et al. analyzed conducted a study with a large cohort com-
posed of patients with subclinical hyperthyroidism and observed a significantly 
higher hospitalizations rate due to heart failure in older patients, especially in 
those with grade 2 subclinical hyperthyroidism [111]. A distinct inverse propor-
tion between TSH level and the risk of AF have been concluded in previous studies 
[112]. Furthermore, current retrospective studies with large cohorts have obviously 
determined a link between subclinical hyperthyroidism and cardiovascular events 
especially heart failure. More importantly, all-cause mortality observed higher in 
this group [113]. The European Thyroid Association recommends full treatment in 
patients older than 65 years with grade 2 subclinical hyperthyroidism. Beyond that, 
same guideline suggests to treat milder grade if any additional heart disease or other 
significant comorbidities or risk factors present [110].
12. Treatment
Recent treatment options for Graves’ hyperthyroidism include antithyroid drugs, 
radioactive iodine, and surgery. In addition β-adrenergic blockade is targeted to 
blockade cathecolamine discharge. The cardiovascular symptoms stimulated by 
hyperthyroidism resolve after an adequate treatment regardless of utilizing radio-
active iodine or antithyroid drug. Hyperthyroidism may exaggerate preexisting 
cardiovascular diseases by increasing demand for myocardial oxygen, contractility 
and heart rate. In such circumstances, silent coronary artery disease, angina or com-
pensated heart failure and even endothelial dysfunction develop [114]. Tachycardia 
control by using β-blockers should be added into treatment in the management of 
heart failure. Nevertheless, possible contraindications have to be considered in each 
individuals. Furosemide may aid to reduce volume overload. However, requirement 
of more Na-K-ATPase in the myocardium due to İncreased blood volume (distribu-
tion) in euthyroid heart failure patients result in relative resistance to digoxin [77]. 
Beta blockers, especially propranolol and atenolol aid to control palpitations by decel-
erating the heart rate in case of sinus tachycardia [115]. Although, all types of calcium 
channel blockers are utilized in the management of newly emerged atrial fibrillation, 
in the presence of thyrotoxicosis, intravenous administration increase adverse effects. 
The vasodilator and negative inotrope effects of these drugs may cause hypotension 
and even cardiovascular collapse [116]. Further precautions are required in case of 
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In case of heart failure resisting despite the heart rate decelerated, or if the 
patient is in advanced age, or has diagnosed or suspected preexisting heart disease, 
or has hypertension standard treatment protocols should be applied. In occasional 
conditions such as hyperthyroidism or thyroid storm requires close cardiovascular 
monitoring and management of other comorbidities (infection, trauma, acute psy-
chiatric illness) [92, 117]. The efficacy of anticoagulant drugs has been less inves-
tigated into correctable causes of AF such as hyperthyroidism. Our clinical routine 
tends to initiate antithrombotic agents as in general population. After euthyroid 
state established, and in the documented absence of AF during at least three 
months, terminating the anticoagulant therapy should be concluded. However, the 
patients should be kept in close follow-up with routine intervals in terms of heart 
rate. Although, some clinics demand further documentation, 24 hours of continu-
ous monitoring without AF and the absence of any sign and symptoms regarding 
AF is sufficient to terminate anticoagulant therapy in our protocol. However, two 
clinicians decide whether to discontinue anticoagulant treatment according to 
CHA2DS2-VASc score, regardless of rhythm.
13. Conclusion
It’s important to bear in mind that significant cardiac complications of Graves’ 
disease (dilated cardiomyopathy, atrial fibrillation, systemic hypertension and 
pulmonary hypertension) may occur in previously fit young patients without 
cardiac disease. All these cardiac complications increase mortality and morbidity in 
patients with Graves’ disease. Most of the time cardiac function recovers if Graves’ 
disease is specifically treated and cardiac interventions are done in a timely fashion. 
Therefore early diagnosis and definitive treatment of hyperthyroidism is crucial for 
prevention of the development of thyrotoxic cardiomyopathy.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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